keyword
MENU ▼
Read by QxMD icon Read
search

tumor lysis syndrome dialysis

keyword
https://www.readbyqxmd.com/read/27119419/impact-of-dialysis-requirement-on-outcomes-in-tumor-lysis-syndrome
#1
Pranav S Garimella, Poojitha Balakrishnan, Natraj R Ammakkanavar, Shanti Patel, Achint Patel, Ioannis Konstantinidis, Narender Annapureddy, Girish N Nadkarni
Tumor lysis syndrome (TLS) is a life threatening emergency due to destruction and massive release of intracellular metabolites from cancer cells often resulting in acute kidney injury (AKI), sometimes severe enough to require dialysis (AKI-D). The impact of dialysis requirement in AKI has not been explored. We utilized data from the Nationwide Inpatient Sample and using International Classification of Diseases, 9th Revision, diagnoses codes for TLS, AKI and dialysis, evaluated the incidence, risk factors and impact of AKI-D on mortality, adverse discharge and length of stay (LOS)...
April 27, 2016: Nephrology
https://www.readbyqxmd.com/read/27084514/single-4-5%C3%A2-mg-fixed-dose-of-rasburicase-for-hyperuricemia-associated-with-tumor-lysis-syndrome
#2
Kajal S Patel, Jessica E Lau, Anthony S Zembillas, Erika M Gallagher
Rasburicase is a recombinant urate oxidase enzyme administered for treatment of hyperuricemia associated with tumor lysis syndrome. Studies demonstrate effectiveness of single fixed-dose rasburicase as compared to the FDA-approved dose of 0.2 mg/kg intravenously daily for up to five days. Doses in these studies range from 1.5 mg to 7.5 mg. Our study evaluated outcomes in patients who received single 4.5 mg fixed-dose rasburicase. This retrospective, IRB-approved chart review evaluated adult oncology subjects who received fixed-dose rasburicase between January 2007 and April 2014...
April 15, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26855510/sevelamer-is-an-effective-drug-in-treating-hyperphosphatemia-due-to-tumor-lysis-syndrome-in-children-a-developing-world-experience
#3
Dilraj Kaur Kahlon, Veronique Dinand, Satya Prakash Yadav, Anupam Sachdeva
We report here a study on efficacy of sevelamer hydrochloride in treating hyperphosphatemia due to tumor lysis syndrome (TLS) in a developing world setting. Twenty one children with hyperphosphatemia due to TLS were included. All received hyper-hydration, allopurinol and sevelamer. Efficacy was assessed by decrease in serum phosphate level, calcium-phosphate product and TLS score as per Cairo Bishop definition. Four children who underwent dialysis were excluded from analysis. Among the remaining 17 patients with hyperphosphatemia, laboratory TLS was recorded in 15 patients and clinical TLS in five...
March 2016: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/26629730/tumor-lysis-syndrome-review-of-pathogenesis-risk-factors-and-management-of-a-medical-emergency
#4
REVIEW
M Criscuolo, L Fianchi, G Dragonetti, L Pagano
Tumor lysis syndrome (TLS) is a rare but potentially life-threatening complication of neoplasms, preferentially hematological malignancies. Well known since at least ninety years ago, this condition can be misdiagnosed and incorrectly managed due to rapid onset of symptoms, sometimes overlapping with cancer-derived clinical conditions. Our purpose is to discuss some old and new issues of this syndrome. Predisposing factors as type of malignancy, chemotherapy regimen and age are promptly available and useful tools for inducing TLS suspicion...
2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/25938028/tumor-lysis-syndrome-a-clinical-review
#5
REVIEW
Aibek E Mirrakhimov, Prakruthi Voore, Maliha Khan, Alaa M Ali
Tumor lysis syndrome is an oncometabolic emergency resulting from rapid cell death. Tumor lysis syndrome can occur as a consequence of tumor targeted therapy or spontaneously. Clinicians should stratify every hospitalized cancer patient and especially those receiving chemotherapy for the risk of tumor lysis syndrome. Several aspects of prevention include adequate hydration, use of uric acid lowering therapies, use of phosphate binders and minimization of potassium intake. Patients at high risk for the development of tumor lysis syndrome should be monitored in the intensive care unit...
May 4, 2015: World Journal of Critical Care Medicine
https://www.readbyqxmd.com/read/25838646/single-dose-rasburicase-in-the-management-of-tumor-lysis-syndrome-in-childhood-acute-lymphoblastic-leukemia-a-case-series
#6
S M Latha, D Krishnaprasadh, P Murugapriya, J X Scott
Tumor lysis syndrome (TLS) occurs in malignancies with high proliferative potential and tumor burden, such as lymphomas and leukemias. TLS syndrome is an oncologic emergency, requiring prompt intervention. The metabolic derangements cause acute kidney failure and may lead to cardiac arrhythmias, seizures, and death. With the advent of rasburicase, a recombinant urate oxidase, there has been a decline in the TLS-mediated renal failure and the need for dialysis. The recommended regimen and doses pose a heavy financial burden for patients in developing countries like India...
March 2015: Indian Journal of Nephrology
https://www.readbyqxmd.com/read/25338496/low-dose-rasburicase-in-hematologic-malignancies
#7
Somasundaram Jayabose, Vignesh Kumar, Rajeswari Dhanabalan, Priya Rajan, Krishnakumar Rathnam, T Kasi Viswanathan
OBJECTIVE: To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies. METHODS: This study is a retrospective analysis of data on 41 children with hematologic malignacies with laboratory evidence of tumor lysis syndrome (TLS) or clinical features indicating high risk for developing TLS. Patients were treated with rasburicase in doses of 0.1-0.15 mg/kg dose, repeated when necessary. RESULTS: Male : Female ratio was 32:9...
May 2015: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/25334183/not-all-tumor-lysis-syndromes-are-due-to-malignancy
#8
Dereddi Raja Reddy, Pramod Guru, Shihab Sugeir, Vivek Iyer
SESSION TITLE: Infectious Disease Student/Resident Case Report Posters IIISESSION TYPE: Medical Student/Resident Case ReportPRESENTED ON: Tuesday, October 28, 2014 at 01:30 PM - 02:30 PMINTRODUCTION: Tumor lysis syndrome (TLS) is commonly seen in hematologic and solid tumor malignancies in association with chemotherapy and sometimes spontaneously. Infection associated TLS has never been described to our knowledge.CASE PRESENTATION: A previously healthy young 29 year old male with h/o polysubstance abuse initially evaluated for intermittent chest pain, shortness of breath and ten pound weight loss in a span of one week...
October 1, 2014: Chest
https://www.readbyqxmd.com/read/24359983/tumor-lysis-syndrome-new-challenges-and-recent-advances
#9
REVIEW
F Perry Wilson, Jeffrey S Berns
Tumor lysis syndrome (TLS) is an oncologic emergency triggered by the rapid release of intracellular material from lysing malignant cells. Most common in rapidly growing hematologic malignancies, TLS has been reported in virtually every cancer type. Central to its pathogenesis is the rapid accumulation of uric acid derived from the breakdown of nucleic acids, which leads to kidney failure by various mechanisms. Kidney failure then limits the clearance of potassium, phosphorus, and uric acid leading to hyperkalemia, hyperphosphatemia, and secondary hypocalcemia, which can be fatal...
January 2014: Advances in Chronic Kidney Disease
https://www.readbyqxmd.com/read/24078288/complications-of-very-high-leukocytosis-in-pediatric-acute-leukemia-patients-managed-without-rasburicase-and-leukopheresis
#10
Sameer Bakhshi, Rajkumar Bikramjit Singh, Khushboo Munot, Subha Pathania
The authors evaluated complications in pediatric acute leukemia with "very high" leukocytosis (VHL) prior to rasburicase availability and without leukopheresis. From Jun 2003 through Dec 2009, 45 out of 457 (10 %) pediatric acute leukemia patients had VHL. Median WBC for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients was 296,500/mm3 (200,000-615,220) and 206,300/mm3 (106,100-541,900) respectively. Laboratory and clinical tumor-lysis-syndrome was seen in 37.7 % and 13.3 % patients respectively; none required dialysis; 6...
August 2014: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/23459539/-tumor-lysis-syndrome-after-transarterial-embolization-for-hepatocellular-carcinoma
#11
Yu Nishida, Hideki Fujii, Atsushi Hagihara, Etsushi Kawamura, Shuji Iwai, Masaru Enomoto, Akihiro Tamori, Tetsuo Arakawa, Norifumi Kawada
A man in his 70's was admitted to our hospital for treatment of a huge hepatocellular carcinoma (HCC) by transcatheter hepatic arterial embolization (TAE). After treatment, anuria occurred, and laboratory examinations revealed a diagnosis of tumor lysis syndrome (TLS). He underwent conservative therapy including hemodialysis, resulting in complete remission of TLS. On the other hand, poor hepatic functional reserve was seen temporarily. After conservative therapy, biochemical markers returned dramatically. TLS is a group of metabolic complications in cancer therapy...
March 2013: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/23224315/-acute-kidney-injury-secondary-to-steroid-induced-tumor-lysis-in-an-adolescent-with-acute-lymphoblastic-leukemia-role-of-urinary-alkalinisation-and-peritoneal-dialysis
#12
Gustavo Roberto Marín, Elena Majek
An adolescent with acute lymphoblastic leukemia developed an early and severe tumor lysis syndrome with acute kidney injury after a low and single dose of steroids. Renal dysfunction was attributed primarily to phosphate nephropathy with nephrocalcinosis due to extreme elevations of phosphate in blood. Urinary alkalinization probably contributed to this development. We used peritoneal dialysis with resolution of nephrocalcinosis and normalization of creatinine clearance.
December 2012: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/22879434/onco-nephrology-tumor-lysis-syndrome
#13
REVIEW
F Perry Wilson, Jeffrey S Berns
Tumor lysis syndrome (TLS) describes the clinical and laboratory sequelae that result from the rapid release of intracellular contents of dying cancer cells. It is characterized by the release of potassium, phosphorous, and nucleic acids from cancer cells into the blood stream, with the potential to cause hyperkalemia; hyperphosphatemia and secondary hypocalcemia; hyperuricemia; AKI; and, should usual homeostatic mechanisms fail, death. TLS most commonly follows treatment of hematologic malignancies, such as acute lymphocytic or lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma, but also occurs after treatment of other bulky or rapidly growing tumors, particularly if the patient is highly sensitive to the effects of cytotoxic chemotherapy...
October 2012: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/22805158/nonrenal-indications-for-continuous-renal-replacement-therapy-a-report-from-the-prospective-pediatric-continuous-renal-replacement-therapy-registry-group
#14
MULTICENTER STUDY
Geoffrey M Fleming, Scott Walters, Stuart L Goldstein, Steven R Alexander, Michelle A Baum, Douglas L Blowey, Timothy E Bunchman, Annabelle N Chua, Sarah A Fletcher, Francisco X Flores, James D Fortenberry, Richard Hackbarth, Kevin McBryde, Michael J G Somers, Jordan M Symons, Patrick D Brophy
OBJECTIVE: Continuous renal replacement therapy is the most often implemented dialysis modality in the pediatric intensive care unit setting for patients with acute kidney injury. However, it also has a role in the management of patients with nonrenal indications such as clearance of drugs and intermediates of disordered cellular metabolism. MEASUREMENTS AND METHODS: Using data from the multicenter Prospective Pediatric Continuous Renal Replacement Therapy Registry, we report a cohort of pediatric patients receiving continuous renal replacement therapy for nonrenal indications...
September 2012: Pediatric Critical Care Medicine
https://www.readbyqxmd.com/read/22752730/tumor-lysis-syndrome
#15
Aruna Rajendran, Deepak Bansal, R K Marwaha, Sunit C Singhi
Tumor lysis syndrome (TLS) refers to the constellation of deranged metabolic state, characterized by hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, and/or azotemia, secondary to rapid breakdown of tumor cells. It is a life threatening emergency that typically follows administration of chemotherapy or may be spontaneous. Malignancies which have a large tumor burden, rapid turnover, as well as speedy breakdown following chemotherapy are susceptible. Acute lymphoblastic leukemia and non-Hodgkins lymphoma (particularly Burkitt's lymphoma) are typically predisposed...
January 2013: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/22490464/tumor-lysis-syndrome-in-patients-with-light-chain-multiple-myeloma-report-of-two-cases
#16
Hung Chang, Shen-Yang Lee, Tzung-Chih Tang
Tumor lysis syndrome (TLS) is a severe life-threatening complication which typically occurs in highly proliferative malignancies, such as Burkitt's lymphoma, acute leukemia or germ cell tumors. Although TLS is unusual in multiple myeloma, it should not be overlooked as it is associated with significant morbidity. In recent years, emerging new agents such as thalidomide and bortezomib have been found to be highly effective in the treatment of multiple myeloma. In this milieu, there is greater concern that the rate of TLS in multiple myeloma will increase...
2011: Chang Gung Medical Journal
https://www.readbyqxmd.com/read/21867622/-clinicopathological-features-of-acute-tumor-lysis-syndrome-in-elderly-patients-with-malignant-non-hodgkin-s-lymphoma
#17
Wen-Ying Zhang, Bo Yang, Xue-Chun Lu, Yang Liu, Yang Yang, Hong-Li Zhu
This study was purposed to investigate the clinicopathological features of acute tumor lysis syndrome (ATLS) in elderly patients with malignant non-Hodgkin's lymphoma, so as to explore its diagnosis and treatments. 2 cases of ATLS in elderly patients with non-Hodgkin's lymphoma were retrospectively analyzed, including progress of tumor, the level of laboratory examination, clinical manifestation and response to treatments. Data regarding clinical and biochemical parameters were collected. The results indicated that the 2 patients with non-Hodgkin's lymphoma were found to have high tumor burden, and were sensitive to anti-tumor treatments, and had many promoting factors of ATLS...
August 2011: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/21618960/how-we-treat-tumor-lysis-syndrome
#18
REVIEW
Alaa Muslimani, Mohammad Muhsin Chisti, Shannon Wills, Laura Nadeau, Dana Zakalik, Hamed Daw, James Huang, Ishmael Jaiyesimi
Tumor lysis syndrome (TLS) is an oncology emergency that occurs as a result of rapid tumor cell breakdown and the consequent release of massive amounts of intracellular contents, including potassium, phosphate, and uric acid, into the systemic circulation. These metabolic disturbances lead to life-threatening conditions and may cause sudden death if not treated. TLS commonly occurs following initiation of cytotoxic treatment in patients with high-grade lymphomas or acute lymphoblastic leukemia. Spontaneous cases involving both solid and hematologic tumors have also been reported...
April 15, 2011: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/21501203/a-review-of-tumour-lysis-syndrome-with-targeted-therapies-and-the-role-of-rasburicase
#19
REVIEW
P Bose, O Qubaiah
WHAT IS KNOWN AND OBJECTIVE: Tumour lysis syndrome (TLS) is an oncologic emergency with potentially devastating consequences classically associated with cytotoxic chemotherapy. In recent years, molecularly targeted drugs have assumed an increasingly important role in cancer therapeutics. The possibility of TLS is often overlooked in this setting. Rasburicase, a recombinant urate oxidase, is remarkably effective in treating hyperuricemia, thought to be central to the pathogenesis of renal injury in TLS...
June 2011: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/21368393/single-dose-of-rasburicase-for-treatment-of-hyperuricemia-in-acute-kidney-injury-a-report-of-3-cases
#20
Nakysa Hooman, Hasan Otukesh
Severe hyperuricemia accompanied by the other comorbidities such as anuria, fluid overload, calcium-phosphate imbalance, and/or tumor lysis syndrome is one of the indications for dialysis in the setting of acute kidney injury. Rasburicase is used in different clinical conditions such as tumor lysis syndrome and uric acid nephropathy. Among referred patients to our center from 2008 to 2010, there were 3 patients who had an indication for dialysis because of hyperuricemia. Contributing factors to the acute kidney injury were multi-organ dysfunction, rapidly progressive glomerulonephritis, and spontaneous tumor lysis syndrome...
March 2011: Iranian Journal of Kidney Diseases
keyword
keyword
57223
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"